Harrison & Star lands Roche Pegasys account

Share this article:
Roche switched professional agencies for its top-selling hepatitis C therapy Pegasys to Omnicom’s Harrison & Star from echo Torre Lazur, part of Interpublic Group’s McCann Healthcare Worldwide. The move followed a three-way pitch among Harrison & Star, GSW and one other agency. Pegasys is the world’s best-selling treatment for chronic hepatitis C. The drug brought in $1.13 billion in revenue last year, a 17% increase over 2004.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.